Mechanism of Complement Activation and Its Role in the Inflammatory Response After Thoracoabdominal Aortic Aneurysm Repair

Background— Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation. Methods and Results— The degree and mechanism of complement activation and it...

Full description

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 108; no. 7; pp. 849 - 856
Main Authors Fiane, Arnt E., Videm, Vibeke, Lingaas, Per S., Heggelund, Lars, Nielsen, Erik W., Geiran, Odd R., Fung, Michael, Mollnes, Tom E.
Format Journal Article
LanguageEnglish
Published United States American Heart Association, Inc 19.08.2003
Subjects
Online AccessGet full text
ISSN0009-7322
1524-4539
1524-4539
DOI10.1161/01.CIR.0000084550.16565.01

Cover

Loading…
Abstract Background— Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation. Methods and Results— The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1β, tumor necrosis factor α (TNF-α), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1β, TNF-α, or IL-8 in a mannose-binding lectin (MBL)–deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients. Conclusions— The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response.
AbstractList Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation.BACKGROUNDComplement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation.The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1beta, tumor necrosis factor alpha (TNF-alpha), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1beta, TNF-alpha, or IL-8 in a mannose-binding lectin (MBL)-deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients.METHODS AND RESULTSThe degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1beta, tumor necrosis factor alpha (TNF-alpha), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1beta, TNF-alpha, or IL-8 in a mannose-binding lectin (MBL)-deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients.The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response.CONCLUSIONSThe data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response.
Background— Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation. Methods and Results— The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1β, tumor necrosis factor α (TNF-α), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1β, TNF-α, or IL-8 in a mannose-binding lectin (MBL)–deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients. Conclusions— The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response.
Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation. The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1beta, tumor necrosis factor alpha (TNF-alpha), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1beta, TNF-alpha, or IL-8 in a mannose-binding lectin (MBL)-deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients. The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response.
BACKGROUND: Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive ischemia-reperfusion and considerable systemic inflammation. METHODS AND RESULTS: The degree and mechanism of complement activation and its role in inflammation were investigated in 19 patients undergoing TAAA repair. Patients undergoing open infrarenal aortic surgery (n=5) or endovascular descending aortic aneurysm repair (n=6) served as control subjects. Substantial complement activation was seen in TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, whereas C4bc, C3bBbP, C3bc, and the terminal SC5b-9 complex (TCC) increased markedly after reperfusion, reaching a maximum 8 hours after reperfusion. Interleukin (IL)-1beta, tumor necrosis factor alpha (TNF-alpha), and IL-8 increased significantly in TAAA patients but not in controls, peaking at 24 hours postoperatively and correlating closely with the degree of complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in the TAAA patients, were not correlated with complement activation, and increased moderately in the control subjects. Myeloperoxidase and lactoferrin increased markedly before reperfusion in all groups, whereas sICAM-1, sP-selectin, and sE-selectin were unchanged. No increase was observed in complement activation products, IL-1beta, TNF-alpha, or IL-8 in a mannose-binding lectin (MBL)-deficient TAAA patient, whereas IL-6, IL-10, myeloperoxidase, and lactoferrin increased as in the controls. Two other MBL-deficient TAAA patients receiving plasma attained significant MBL levels and showed complement and cytokine patterns identical to the MBL-sufficient TAAA patients. CONCLUSIONS: The data suggest that complement activation during TAAA repair is MBL mediated, amplified through the alternative pathway, and responsible in part for the inflammatory response.
Author Heggelund, Lars
Lingaas, Per S.
Fiane, Arnt E.
Fung, Michael
Videm, Vibeke
Geiran, Odd R.
Mollnes, Tom E.
Nielsen, Erik W.
Author_xml – sequence: 1
  givenname: Arnt E.
  surname: Fiane
  fullname: Fiane, Arnt E.
  organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V
– sequence: 2
  givenname: Vibeke
  surname: Videm
  fullname: Videm, Vibeke
  organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V
– sequence: 3
  givenname: Per S.
  surname: Lingaas
  fullname: Lingaas, Per S.
  organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V
– sequence: 4
  givenname: Lars
  surname: Heggelund
  fullname: Heggelund, Lars
  organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V
– sequence: 5
  givenname: Erik W.
  surname: Nielsen
  fullname: Nielsen, Erik W.
  organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V
– sequence: 6
  givenname: Odd R.
  surname: Geiran
  fullname: Geiran, Odd R.
  organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V
– sequence: 7
  givenname: Michael
  surname: Fung
  fullname: Fung, Michael
  organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V
– sequence: 8
  givenname: Tom E.
  surname: Mollnes
  fullname: Mollnes, Tom E.
  organization: From the Department of Thoracic and Cardiovascular Surgery (A.E.F., P.S.L., O.R.G.), Research Institute for Internal Medicine and Section of Clinical Immunology and Infectious Diseases (L.H.), and Institute of Immunology (T.E.M.), Rikshospitalet University Hospital, Oslo, Norway; Department of Immunology and Transfusion Medicine, Trondheim University Hospital, and Institute of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway (V.V
BackLink https://www.ncbi.nlm.nih.gov/pubmed/12900342$$D View this record in MEDLINE/PubMed
BookMark eNqNkV1rHCEUhqWkNJu0f6FILno3Wz_GUXvVYenHQkphSa_FcRzWMOpUncD219d8lECu6o34-pxz0OcCnIUYLABXGG0x7vBHhLe7_WGL7pdoGatxxzq2RfgV2GBG2qZlVJ6BTb2XDaeEnIOLnG_rsaOcvQHnmEiEaEs24M8Pa446uOxhnOAu-mW23oYCe1PcnS4uBqjDCPclw0OcLXQBlqOF-zDN2ntdYjrBg81LDNnCfio2wZtjTNpEPYzRu6Bn2MdUnIF9sGs61UkHu2iX3oLXk56zffe0X4JfX7_c7L431z-_7Xf9dWOooKXhujXUjELKjgySEo06zjrRSmGkplTzGmsqcEflRJGoIG8RaydJiB3GgdFL8OGx75Li79XmorzLxs6zDjauWXHKOBGcV_DqBXgb11QfkBXBhFMsJKrQ-ydoHbwd1ZKc1-mk_n1pBT49AibFnJOdnhGk7v0phFX1p579qQd_Na_Fn18UG1ceLJSk3fw_Lf4CLf2gzg
CODEN CIRCAZ
CitedBy_id crossref_primary_10_1080_14017430802302316
crossref_primary_10_1172_JCI31311
crossref_primary_10_2478_v10011_012_0004_3
crossref_primary_10_2310_6670_2006_00061
crossref_primary_10_4049_jimmunol_177_12_8626
crossref_primary_10_1007_s00772_018_0432_6
crossref_primary_10_1007_s13126_010_0015_9
crossref_primary_10_1007_s12035_014_8941_0
crossref_primary_10_1002_art_22302
crossref_primary_10_1016_S1877_8607_09_60008_4
crossref_primary_10_1111_j_1600_6143_2009_02675_x
crossref_primary_10_1016_j_molimm_2009_04_028
crossref_primary_10_1097_SLA_0b013e3181784cc5
crossref_primary_10_1002_art_22662
crossref_primary_10_1038_s41598_024_63412_1
crossref_primary_10_1111_j_1537_2995_2007_01585_x
crossref_primary_10_1016_j_molimm_2008_02_011
crossref_primary_10_1111_j_1365_2249_2004_02489_x
crossref_primary_10_1016_j_amjcard_2024_04_007
crossref_primary_10_1016_j_ejvs_2005_09_012
crossref_primary_10_1007_s00380_010_0056_6
crossref_primary_10_1002_14651858_CD012926_pub2
crossref_primary_10_1038_ki_2012_373
crossref_primary_10_1016_S0002_9440_10_63424_4
crossref_primary_10_1016_j_jim_2007_04_004
crossref_primary_10_1038_sj_bjp_0706286
crossref_primary_10_1097_SLA_0b013e3181a38f45
crossref_primary_10_1007_s00772_019_0510_4
crossref_primary_10_1111_j_1445_2197_2007_04098_x
crossref_primary_10_3390_jcm11092501
crossref_primary_10_3389_fimmu_2022_852119
crossref_primary_10_1016_j_avsg_2016_03_031
crossref_primary_10_1007_s12035_014_8682_0
crossref_primary_10_1021_acs_analchem_4c04416
crossref_primary_10_3389_fimmu_2023_1290684
crossref_primary_10_1016_j_ejca_2005_10_027
crossref_primary_10_1016_j_jvs_2007_08_032
crossref_primary_10_1016_j_avsg_2022_12_075
crossref_primary_10_1016_j_molimm_2006_06_020
crossref_primary_10_1007_s00268_005_7877_y
crossref_primary_10_1016_j_imbio_2012_07_019
crossref_primary_10_1186_1471_2334_12_144
crossref_primary_10_1590_0102_6720201600010015
crossref_primary_10_2337_diabetes_54_5_1523
crossref_primary_10_4049_jimmunol_175_1_541
crossref_primary_10_2337_diabetes_53_6_1570
crossref_primary_10_3390_ijms18112374
crossref_primary_10_1053_j_jvca_2012_09_013
crossref_primary_10_1016_j_cellimm_2014_04_006
crossref_primary_10_1097_01_mot_0000127627_94212_76
crossref_primary_10_1007_s00595_007_3575_8
crossref_primary_10_2147_JIR_S344489
crossref_primary_10_3390_cells10071810
crossref_primary_10_1038_aps_2017_212
crossref_primary_10_1007_s10047_011_0577_5
crossref_primary_10_1016_j_athoracsur_2005_11_059
crossref_primary_10_1016_j_molimm_2005_06_014
crossref_primary_10_1016_j_cardfail_2006_07_002
crossref_primary_10_1016_j_avsg_2013_08_005
crossref_primary_10_1007_s00005_009_0029_6
crossref_primary_10_1038_aps_2011_151
crossref_primary_10_1111_j_1365_2249_2006_03072_x
crossref_primary_10_1093_eurheartj_ehi198
crossref_primary_10_1186_s12893_020_00851_3
crossref_primary_10_1016_j_molimm_2006_10_003
crossref_primary_10_1177_0267659108097882
crossref_primary_10_1161_JAHA_124_036539
crossref_primary_10_4049_jimmunol_174_10_6373
crossref_primary_10_4103_bc_bc_133_24
crossref_primary_10_1007_s11064_013_1214_x
crossref_primary_10_1177_1479164109336051
Cites_doi 10.1016/0167-5699(87)90167-8
10.1016/S0002-9440(10)65026-2
10.1161/circ.104.12.1413
10.1016/S0162-3109(00)80303-3
10.1084/jem.180.5.1619
10.1016/0022-1759(93)90240-8
10.1016/S0002-9440(10)63839-4
10.1126/science.2371562
10.3109/00365518509155248
10.1161/circ.91.2.393
10.2165/00063030-200115090-00004
10.1006/jsre.2002.6385
10.1111/j.1365-3083.1988.tb02354.x
10.1046/j.1472-8206.2001.00040.x
10.1097/00024382-199609010-00003
10.1002/bjs.1800840209
10.1111/j.1365-3083.1985.tb01871.x
10.1046/j.1365-3083.1996.d01-57.x
10.1016/S0162-3109(99)00029-6
10.1097/00003246-200009000-00013
10.1016/S0161-5890(99)00118-2
10.1046/j.1365-3083.1997.d01-168.x
10.1093/cvr/28.4.437
10.1016/S0003-4975(97)00958-2
10.1084/jem.183.5.2343
10.1053/ejvs.2000.1147
10.1016/S0741-5214(97)70154-X
10.1152/jappl.1999.86.3.938
10.1016/S0022-1759(01)00453-7
10.1517/13543784.9.5.975
ContentType Journal Article
Copyright Copyright American Heart Association, Inc. Aug 19 2003
Copyright_xml – notice: Copyright American Heart Association, Inc. Aug 19 2003
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
U9A
7X8
DOI 10.1161/01.CIR.0000084550.16565.01
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Career and Technical Education (Alumni Edition)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1524-4539
EndPage 856
ExternalDocumentID 388112281
12900342
10_1161_01_CIR_0000084550_16565_01
Genre Controlled Clinical Trial
Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.-D
.3C
.55
.GJ
.XZ
.Z2
01R
0R~
0ZK
18M
1J1
29B
2FS
2WC
354
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6PF
71W
77Y
7O~
AAAAV
AAAXR
AAFWJ
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AARTV
AASOK
AAUEB
AAWTL
AAXQO
AAYOK
AAYXX
ABBUW
ABDIG
ABJNI
ABOCM
ABPMR
ABPXF
ABQRW
ABXVJ
ABZAD
ACCJW
ACDDN
ACDOF
ACEWG
ACGFO
ACGFS
ACILI
ACOAL
ACRKK
ACWDW
ACWRI
ACXNZ
ACZKN
ADBBV
ADCYY
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFCHL
AFDTB
AFEXH
AFFNX
AFNMH
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
ALKUP
ALMA_UNASSIGNED_HOLDINGS
AMJPA
AMNEI
ASPBG
AVWKF
AYCSE
AZFZN
BAWUL
BOYCO
BQLVK
BS7
BYPQX
C1A
C45
CITATION
CS3
DIK
DIWNM
DU5
DUNZO
E.X
E3Z
EBS
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FEDTE
FL-
FW0
GX1
H0~
H13
HVGLF
HZ~
H~9
IKREB
IKYAY
IN~
J5H
JF9
JG8
JK3
JK8
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
M18
N4W
N9A
NEJ
N~7
N~B
N~M
O9-
OAG
OAH
OBH
OCB
OCUKA
ODA
ODMTH
OGEVE
OHH
OHT
OHYEH
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P2P
PQQKQ
R58
RAH
RLZ
S4R
S4S
T8P
TEORI
TR2
UPT
V2I
VVN
W2D
W3M
W8F
WH7
WHG
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YOC
YSK
YYM
YYP
YZZ
ZFV
ZGI
ZXP
ZY1
ZZMQN
~H1
ACIJW
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
OJAPA
OLW
PKN
RHF
K9.
NAPCQ
U9A
7X8
ID FETCH-LOGICAL-c383t-7a4c3cd89962b932a067568498c9a33a762ba381639f308d8974054f922ebdb53
ISSN 0009-7322
1524-4539
IngestDate Sun Aug 24 04:04:26 EDT 2025
Fri Jul 25 07:00:23 EDT 2025
Wed Feb 19 01:34:03 EST 2025
Thu Apr 24 22:58:07 EDT 2025
Tue Jul 01 02:06:24 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c383t-7a4c3cd89962b932a067568498c9a33a762ba381639f308d8974054f922ebdb53
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
content type line 23
PMID 12900342
PQID 212731890
PQPubID 24119
PageCount 8
ParticipantIDs proquest_miscellaneous_73572877
proquest_journals_212731890
pubmed_primary_12900342
crossref_primary_10_1161_01_CIR_0000084550_16565_01
crossref_citationtrail_10_1161_01_CIR_0000084550_16565_01
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2003-08-19
2003-Aug-19
20030819
PublicationDateYYYYMMDD 2003-08-19
PublicationDate_xml – month: 08
  year: 2003
  text: 2003-08-19
  day: 19
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Baltimore
PublicationTitle Circulation (New York, N.Y.)
PublicationTitleAlternate Circulation
PublicationYear 2003
Publisher American Heart Association, Inc
Publisher_xml – name: American Heart Association, Inc
References e_1_3_3_17_2
e_1_3_3_19_2
e_1_3_3_18_2
e_1_3_3_13_2
e_1_3_3_12_2
(e_1_3_3_20_2) 2002; 100
e_1_3_3_15_2
e_1_3_3_14_2
e_1_3_3_32_2
e_1_3_3_33_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_10_2
e_1_3_3_31_2
(e_1_3_3_16_2) 1999; 4
e_1_3_3_6_2
e_1_3_3_5_2
e_1_3_3_8_2
e_1_3_3_7_2
e_1_3_3_28_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_29_2
e_1_3_3_24_2
e_1_3_3_23_2
e_1_3_3_26_2
e_1_3_3_25_2
e_1_3_3_2_2
e_1_3_3_1_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_3_2
e_1_3_3_21_2
References_xml – ident: e_1_3_3_2_2
  doi: 10.1016/0167-5699(87)90167-8
– ident: e_1_3_3_29_2
  doi: 10.1016/S0002-9440(10)65026-2
– ident: e_1_3_3_30_2
  doi: 10.1161/circ.104.12.1413
– ident: e_1_3_3_1_2
  doi: 10.1016/S0162-3109(00)80303-3
– ident: e_1_3_3_3_2
  doi: 10.1084/jem.180.5.1619
– ident: e_1_3_3_19_2
  doi: 10.1016/0022-1759(93)90240-8
– ident: e_1_3_3_31_2
  doi: 10.1016/S0002-9440(10)63839-4
– ident: e_1_3_3_6_2
  doi: 10.1126/science.2371562
– ident: e_1_3_3_24_2
  doi: 10.3109/00365518509155248
– ident: e_1_3_3_27_2
  doi: 10.1161/circ.91.2.393
– ident: e_1_3_3_11_2
  doi: 10.2165/00063030-200115090-00004
– ident: e_1_3_3_5_2
  doi: 10.1006/jsre.2002.6385
– ident: e_1_3_3_21_2
  doi: 10.1111/j.1365-3083.1988.tb02354.x
– ident: e_1_3_3_10_2
  doi: 10.1046/j.1472-8206.2001.00040.x
– ident: e_1_3_3_15_2
  doi: 10.1097/00024382-199609010-00003
– ident: e_1_3_3_12_2
  doi: 10.1002/bjs.1800840209
– ident: e_1_3_3_22_2
  doi: 10.1111/j.1365-3083.1985.tb01871.x
– ident: e_1_3_3_23_2
  doi: 10.1046/j.1365-3083.1996.d01-57.x
– ident: e_1_3_3_28_2
  doi: 10.1016/S0162-3109(99)00029-6
– ident: e_1_3_3_13_2
  doi: 10.1097/00003246-200009000-00013
– ident: e_1_3_3_8_2
  doi: 10.1016/S0161-5890(99)00118-2
– ident: e_1_3_3_18_2
  doi: 10.1046/j.1365-3083.1997.d01-168.x
– ident: e_1_3_3_7_2
  doi: 10.1093/cvr/28.4.437
– ident: e_1_3_3_4_2
  doi: 10.1016/S0003-4975(97)00958-2
– ident: e_1_3_3_25_2
  doi: 10.1084/jem.183.5.2343
– ident: e_1_3_3_33_2
  doi: 10.1053/ejvs.2000.1147
– ident: e_1_3_3_14_2
  doi: 10.1016/S0741-5214(97)70154-X
– ident: e_1_3_3_26_2
  doi: 10.1152/jappl.1999.86.3.938
– volume: 100
  start-page: 1869
  year: 2002
  ident: e_1_3_3_20_2
  publication-title: Blood
– ident: e_1_3_3_17_2
  doi: 10.1016/S0022-1759(01)00453-7
– volume: 4
  start-page: 751
  year: 1999
  ident: e_1_3_3_16_2
  publication-title: Cardiol Clin North Am
– ident: e_1_3_3_32_2
– ident: e_1_3_3_9_2
  doi: 10.1517/13543784.9.5.975
SSID ssj0006375
Score 2.068412
Snippet Background— Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer...
Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer extensive...
BACKGROUND: Complement activation contributes to ischemia-reperfusion injury. Patients undergoing thoracoabdominal aortic aneurysm (TAAA) repair suffer...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 849
SubjectTerms Aged
Aged, 80 and over
Aortic Aneurysm, Abdominal - complications
Aortic Aneurysm, Abdominal - surgery
Aortic Aneurysm, Thoracic - complications
Aortic Aneurysm, Thoracic - surgery
Cell Adhesion Molecules - metabolism
Chemokines - blood
Complement Activation - physiology
Cytokines - blood
Female
Humans
Inflammation - blood
Inflammation - etiology
Inflammation - physiopathology
Lactoferrin - metabolism
Male
Mannose-Binding Lectin - deficiency
Mannose-Binding Lectin - metabolism
Middle Aged
Neutrophil Activation
Peroxidase - metabolism
Plasma
Prospective Studies
Reperfusion Injury - etiology
Reperfusion Injury - physiopathology
Vascular Surgical Procedures - adverse effects
Title Mechanism of Complement Activation and Its Role in the Inflammatory Response After Thoracoabdominal Aortic Aneurysm Repair
URI https://www.ncbi.nlm.nih.gov/pubmed/12900342
https://www.proquest.com/docview/212731890
https://www.proquest.com/docview/73572877
Volume 108
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELZCkRAXBC2PtDx8QNw2bNb7PEahUQppQShBuVle29uuaHfRdnNo_wP_mfFjH4VUFC6ryBvHlufLjMf-ZgahtwEPpUgC3xmTVDi-kJmTJMJ1hKt4NoFQdkexLU7C-cr_uA7Wg8HPHmtpU6cjfr01ruR_pAptIFcVJfsPkm1_FBrgM8gXniBheN5JxsdSxe2qMhcNOVwazjhvipZ1dwOKRWg5jTA04ODC3K9XhiQrbbXw-gwwwUuWitKU-2JlZXK6Slh9GKkC-5VX_T3tNK-4LQK2rbZP76xhlltm7aSCWbYxEN9UkVpNuM1T-b1F2kJV6zbxZl9gZu2udS5PT-X5xpyIL1h18-SCqKNYqx-tsvV8xw9MMqOR3NLWaGg37kEx6unb2OQ7_dMOhGMd2zCaHn01KSpjFb49UrmGVJ7Wzvo1N_4nn-lstVjQ5eF6eQ_d98DrUHr-w9Gn1rCHROdtbqdoc9jCWO9vH-nmfucWJ0ZvZpaP0SPrheCJgdQTNJDFLtqbFACJiyv8DmtesL5w2UUPji39Yg9dt4DDZYY7wOEOcBgAhwFwWAEO5wUGwOE-4HADOKwBh38HHDaAww3gsAHcU7SaHS6nc8cW73A4iUntRMznhAtw50MvBSeBKdc0BHnFPGGEMDDCKVO31iTJiBvDFyPwHfws8TyZijQgz9BOURbyBcIBByvhCs5SkviMu8zjEQNlkhEmuAjDIUqaJabcZrZXBVbOqfZwwzF1xxTEQzvxUC0eaB8i0vb9YfK73KnXQSNJavXBJVW1EsBCJu4QvWnfgrJWN3CwZuXmkkYkiLw4iobouRF_N6aX6Gyc-3_te4Aedn-ml2inrjbyFWyM6_S1husvaT600Q
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanism+of+complement+activation+and+its+role+in+the+inflammatory+response+after+thoracoabdominal+aortic+aneurysm+repair&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Fiane%2C+Arnt+E&rft.au=Videm%2C+Vibeke&rft.au=Lingaas%2C+Per+S&rft.au=Heggelund%2C+Lars&rft.date=2003-08-19&rft.issn=1524-4539&rft.eissn=1524-4539&rft.volume=108&rft.issue=7&rft.spage=849&rft_id=info:doi/10.1161%2F01.CIR.0000084550.16565.01&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon